HRT Financial’s Forte Biosciences FBRX Stock Holding History

HRT Financial’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.04M	Buy	+40,000	New	+$1.15M	﹤0.01%	2026

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

HRT Financial's FBRX Position: Q2 2021 in Review

HRT Financial sold out of Forte Biosciences (FBRX) in Q2 2021, closing a stake of 1,270 shares — an estimated $1.09M sold.

HRT Financial first reported a position in FBRX in Q1 2020 and held it in 3 quarters. The position peaked at $1.09M in Q1 2021. 75 funds tracked by Wall St. Rank hold FBRX as of Q2 2021.

HRT Financial reported no remaining Forte Biosciences position as of Q2 2021 after selling out during the quarter.
HRT Financial sold 1,270 Forte Biosciences shares in Q2 2021, an estimated $1.09M.
HRT Financial first reported a position in Forte Biosciences in Q1 2020 and held it in 3 quarters.
HRT Financial's Forte Biosciences position peaked at $1.09M in Q1 2021.
75 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2021.

Based on HRT Financial's 13F filing for Q2 2021, filed 16 Aug 2021.